News

The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies’ next-generation sequencing (NGS) devices. Partek Genomics Suite

According to American Regent, potassium phosphates injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, belonging to lot number 48 is being

Bayer had initiated patient enrolment for a randomised, double-blind, placebo-controlled Phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with

The new investigational regimen, termed as 572-Trii, will combine the investigational integrase inhibitor S/GSK1349572 (‘572) and ViiV Healthcare’s combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa/Epzicom (ABC/3TC). The multi-centre,

Subsequently, Galapagos has regained worldwide rights for all assets developed in its strategic alliances with Merck & Co, through an affiliate. Merck will make a payment of EUR12m

The $300m transaction is expected to increase profitability of the brand for BLS which had previously been the exclusive distributor in the US, and expands BLS’ geographic rights

The objective of the study was to explore safety and tolerability in the sleep apnea population, and assess putative efficacy of CX1739 on a range of sleep apnea

DSC127 is a patented, topically applied novel angiotensin analog that targets receptors that are up-regulated following injury to tissue. The double-blind, placebo-controlled, multi-centre clinical trial enrolled 80 patients

Quercetin is a natural polyphenolic antioxidant flavonoid found in many plants, and plays an important role in the inhibition of enzymes involved in free radical production. It can